Adagio Medical Holdings ADGM
vCLAS awaits a Q4 2026 FDA decision while Adagio seeks a buyer or financing
- vCLAS Ventricular Ablation System FiledVentricular Tachycardia · Ultra-Low Temperature Cryoablation (ULTA) catheter ablation
$129.8B of 2025 cardiometabolic blockbuster sales lose US exclusivity by 2037, led by Mounjaro, Ozempic, Eliquis. These 15 public biotechs have 15 cardiometabolic treatments in Phase 3 or filed with the FDA, 2 of them already filed.
2025 sales each company reports from tracked cardiometabolic treatments losing US exclusivity by 2037. Big pharma has spent $24.4B on 8 cardiometabolic acquisitions since 2023. See the deals →
vCLAS awaits a Q4 2026 FDA decision while Adagio seeks a buyer or financing
Gossamer filed seralutinib on a missed Phase 3; FDA's filing decision unlocks $125 million
Pemvidutide advances across MASH, AUD and ALD; fibrosis benefit remains the pivotal question
Amylyx plans to submit an NDA for avexitide in post-bariatric hypoglycemia by year-end after the Phase 3 LUCIDITY trial cut serious low-blood-sugar events by 55%; an August offering raised $471.7 million net to fund a 2027 launch
REDEMPLO is approved in FCS; the larger severe hypertriglyceridemia filing comes by year-end
MYQORZO is approved in five markets; FDA rules on its MAPLE-HCM label November 14
Inhibikase's IKT-001, an imatinib prodrug, is enrolling the two-part IMPROVE-PAH Phase 3 in pulmonary arterial hypertension; it must deliver imatinib's benefit with better tolerability
FDA accepted Intellia's BLA for lonvo-z in hereditary angioedema with Priority Review and a March 10, 2027 decision date; both nex-z Phase 3 trials resumed enrollment after FDA lifted its clinical holds
Inventiva expects NATiV3 Phase 3 topline results for lanifibranor in MASH in the fourth quarter of 2026; its current cash lasts to the end of the second quarter of 2027
Liquidia settled all litigation with United Therapeutics: YUTREPIA stays on the market in PAH, the PH-ILD label goes, and $380.7 million is due
Obicetrapib won EU approval as Ubeslo and Evlarco, sold in Europe by partner Menarini; NewAmsterdam expects the PREVAIL cardiovascular outcomes interim analysis result in the first quarter of 2027
Longer runway supports ersodetug plans; upLIFT and congenital HI filing remain pivotal
Structure's oral GLP-1 pill aleniglipron is in Phase 3, with three data sets due
Cash supports pivotal development; VANQUISH results remain central
Cadisegliatin's Phase 3 is fully enrolled; hypoglycemia results now expected mid 2027
Filed treatments are listed first. This shows where late-stage treatments are being developed, not which companies will be acquired.
Pipeline data and summaries from Readouts as of 13 November 2026; companies already acquired are left out.
Oncology · Immunology · Infectious disease · Neuroscience · Other areas